Off-label Use of Oral Immunotherapy for Rhinoconjunctivitis and Asthma due to Grass Pollen: A Safe and Effective Alternative in Patients over 65 Years Old: A Series of Case Reports
Authors:
- 1 November 2023
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 18 (4) , 599-602
Abstract
Introduction: Allergic rhinoconjunctivitis and asthma are the most common IgE-mediated diseases worldwide. Allergen-specific immunotherapy (AIT) is currently the only modifying treatment for these IgE-mediated diseases, in both children and adults. Subcutaneous immunotherapy is widely used, but in patients over 65 years old there may be an increased risk of adverse reactions and a worse response to treatment. Oral immunotherapy (OIT) has been proved to be effective and safe, but currently, in most countries, it has been licensed only for patients up to 65 years old based on its technical datasheet. No studies into the efficacy and safety of this type of immunotherapy in patients older than 65 years old have been published. Case Presentation: We present four patients older than 65 years old with a diagnosis of moderate seasonal rhinoconjunctivitis and moderate-persistent seasonal pollen-induced asthma. Off-label use of oral immunotherapy (OIT) for grass pollen was prescribed, due to the severity of their rhinoconjunctivitis symptoms and worsening of asthma symptoms during the spring. Improvement in the rhinoconjunctivitis and asthma symptoms was reported by all patients since the first spring season and was maintained during the following two years of follow-up. There were no systemic reactions and only two patients initially had self-limiting oral pruritus Conclusion: Oral immunotherapy for pollens appears to be a convenient, effective, and safe option in older patients (>65 years) with comorbidities after a three-year treatment. This is, to the best of our knowledge, the first report of the off-label use of OIT in patients over 65 years old with symptoms of allergic rhinoconjunctivitis and asthma.Keywords
This publication has 9 references indexed in Scilit:
- Safety Review of 5-Grass Pollen Tablet from Pooled Data of Clinical TrialsThe Journal of Allergy and Clinical Immunology: In Practice, 2017
- Grazax sublingual immunotherapy in pre–co-seasonal and continuous treatment regimens: is there a difference in clinical efficacy?Annals of Allergy, Asthma & Immunology, 2015
- Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experienceExpert Review of Clinical Immunology, 2014
- Sublingual immunotherapy: World Allergy Organization position paper 2013 updateWorld Allergy Organization Journal, 2014
- Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus reportJournal of Allergy and Clinical Immunology, 2013
- Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta‐analysisClinical & Experimental Allergy, 2011
- Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading SystemJournal of Allergy and Clinical Immunology, 2010
- Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 yearsJournal of Allergy and Clinical Immunology, 2008
- Sublingual immunotherapy: A comprehensive reviewJournal of Allergy and Clinical Immunology, 2006